bevenopran
Small moleculeexperimental
Bevenopran is a peripherally acting μ-opioid receptor antagonist that also acts on δ-opioid receptors and was under development by Cubist Pharmaceuticals for the treatment of chronic opioid-induced constipation. It reached phase III clinical trials for this indication before being discontinued. — Wikipedia
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
6
Phase 3
4
Phase 4
0
Earliest trial started Oct 1, 2010 (NCT01207427)
Timeline
Indications
Mechanism of action
- Mu opioid receptorANTAGONIST
OPRM antagonist
All phase 3 studies have been terminated.
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc(CNCCC2CCOCC2)ccc1Oc1cnc(C(N)=O)cn1- Mol. weight
- 386.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBevenopran ↗
- ChEMBLCHEMBL3039511 ↗
Also known as
- adl5945
- bevenopran
- bevenopran
- bevenopran
- bevenopran
- cb-5945
- cb5-945
- cb5-945
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02508740 | Phase 1 | Sep 1, 2013 | Cubist, INC Research |
| NCT01901328 | Phase 3 | Aug 1, 2013 | Cubist |
| NCT01901302 | Phase 3 | Jul 1, 2013 | Cubist |
| NCT01901341 | Phase 3 | Jul 1, 2013 | Cubist |
| NCT01696643 | Phase 3 | Oct 1, 2012 | Cubist |
| NCT01275755 | Phase 2 | Jan 1, 2011 | Cubist |
| NCT01207427 | Phase 2 | Oct 1, 2010 | Cubist |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cubist | For profit | 7 | 7 | 3 | 2010 |
| INC Research | For profit | 1 | 0 | 1 | 2013 |
2 organizations
Page 1 / 1